Table 1 Clinicopathological characteristics of study patients.
All patients | DDIR-positive | DDIR-negative | ||
|---|---|---|---|---|
(n = 46) | (n = 26) | (n = 20) | ||
Age at diagnosis (years) | 28–64 | 35–64 | 28–58 | P = 0.813a |
(median = 47) | (median = 47) | (median = 48) | ||
ER-positive HER2-negative | 27 (59%) | 13 (48%) | 14 (52%) | P = 0.41b |
HER2-positive (n) | 16 (35%) | 9 (56%) | 7 (44%) | |
ER+ HER2+ | 11 (24%) | 5 (45%) | 6 (55%) | |
ER− HER2+ | 5 (11%) | 4 (80%) | 1 (20%) | |
Triple-negative | 13 (28%) | 8 (62%) | 5 (38%) | |
T stage | P = 0.37c | |||
T2 | 27 | 17 (63%) | 10 (37%) | |
T3 | 19 | 9 (47%) | 10 (53%) | |
N | P = 0.23c | |||
Neg | 12 | 5 (42%) | 7 (58%) | |
Pos | 34 | 21 (62%) | 13 (38%) | |
Grade | P = 0.02b* | |||
2 | 14 | 4 (29%) | 10 (71%) | |
2/3 | 6 | 3 (50%) | 3 (50%) | |
3 | 26 | 19 (73%) | 7 (27%) | |
Treatment regimen | P = 0.35c | |||
FEC 100 | 8 | 3 (37%) | 5 (63%) | |
FEC-taxane | 38 | 23 (61%) | 15 (39%) | |
Neoadjuvant anti-HER2-targeted treatment | 13 | 5 (38%) | 8 (62%) | |
Pre-treatment SLNB | 16 | 8 | 8 | P = 0.57c |
SLNB +ve | 4 | 3 (75%) | 1 (25%) | |
SLNB −ve | 12 | 5 (42%) | 7 (58%) | |
RCB class | P = 0.03c* | |||
RCB0-1 | 18 | 14 (78%) | 4 (22%) | |
RCB2-3 | 28 | 12 (43%) | 16 (57%) |
